CTOs on the Move

Biogen Idec

www.biogenidec.com

 
We are a global biotechnology company, specializing in discovering, developing, and delivering innovative therapies for the treatment of neurodegenerative, non-malignant hematologic and autoimmune diseases to patients worldwide. As a company, we are focused on cutting-edge science and medicines that address unmet patient needs and change the course of these devastating diseases. Founded in 1978, we are the world`s oldest independent biotechnology company and take pride in being known for pioneering the development of leading multiple sclerosis therapies.    With approximately 7,000 employees worldwide, we are focused on better understanding the underlying biology of diseases so we can discover and deliver innovative treatments ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

GABA Therapeutics,

A New Dawn for Central Nervous System Treatments GABA Therapeutics is developing GRX-917, an anxiety medication as effective as benzodiazepines like Xanax, but with minimal to no side effects. The drugs dual mechanism of action may also benefit ...

Prothena

Prothena Corporation plc (Nasdaq: PRTA) Prothena is a global biotechnology company seeking to fundamentally alter the course of progressive diseases. We are a late-stage clinical company focused on the discovery, development, and commercialization of novel protein immunotherapies for the treatment of diseases that involve protein misfolding and inflammatory cell adhesion disorders. Our team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prothena`s pipeline focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins and our antibody-based product candidates target a number of potential indications, including AL amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), ATTR amyloidosis (PRX004), and novel cell adhesion targets involved in psoriasis, psoriatic arthritis and other inflammatory diseases (PRX003). Prior to December 2012, Prothena’s business operated as part of Elan Corporation, plc. Prothena’s business consists of a substantial portion of Elan’s former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan’s stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012.

Stone Clinical Laboratories

The most innovative, patient and provider focused preventative diagnostic laboratory in the industry

RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020

OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining.